Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply
Autor*in: |
André, Thierry [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Übergeordnetes Werk: |
Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London |
---|---|
Übergeordnetes Werk: |
volume:23 ; year:2022 ; number:6 ; pages:246 |
Links: |
---|
DOI / URN: |
10.1016/S1470-2045(22)00299-6 |
---|
Katalog-ID: |
ELV057857385 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV057857385 | ||
003 | DE-627 | ||
005 | 20230625003307.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220808s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/S1470-2045(22)00299-6 |2 doi | |
028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001787.pica |
035 | |a (DE-627)ELV057857385 | ||
035 | |a (ELSEVIER)S1470-2045(22)00299-6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 570 |q VZ |
084 | |a BIODIV |q DE-30 |2 fid | ||
084 | |a 35.70 |2 bkl | ||
084 | |a 42.12 |2 bkl | ||
100 | 1 | |a André, Thierry |e verfasserin |4 aut | |
245 | 1 | 0 | |a Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply |
264 | 1 | |c 2022 | |
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
700 | 1 | |a Diaz, Luis A |4 oth | |
700 | 1 | |a Shiu, Kai-Keen |4 oth | |
773 | 0 | 8 | |i Enthalten in |n The Lancet Publ. Group |a Citovsky, Vitaly ELSEVIER |t My |d 2019 |g London |w (DE-627)ELV003173852 |
773 | 1 | 8 | |g volume:23 |g year:2022 |g number:6 |g pages:246 |
856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(22)00299-6 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a FID-BIODIV | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 35.70 |j Biochemie: Allgemeines |q VZ |
936 | b | k | |a 42.12 |j Biophysik |q VZ |
951 | |a AR | ||
952 | |d 23 |j 2022 |e 6 |h 246 |y 23.2022, 6, e246- |
author_variant |
t a ta |
---|---|
matchkey_str |
andrthierrydiazluisashiukaikeen:2022----:rsiguvvluvsfent17lutaehrtoaeeidobnnimncekonihb |
hierarchy_sort_str |
2022 |
bklnumber |
35.70 42.12 |
publishDate |
2022 |
allfields |
10.1016/S1470-2045(22)00299-6 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001787.pica (DE-627)ELV057857385 (ELSEVIER)S1470-2045(22)00299-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl André, Thierry verfasserin aut Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Diaz, Luis A oth Shiu, Kai-Keen oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:6 pages:246 https://doi.org/10.1016/S1470-2045(22)00299-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 6 246 23.2022, 6, e246- |
spelling |
10.1016/S1470-2045(22)00299-6 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001787.pica (DE-627)ELV057857385 (ELSEVIER)S1470-2045(22)00299-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl André, Thierry verfasserin aut Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Diaz, Luis A oth Shiu, Kai-Keen oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:6 pages:246 https://doi.org/10.1016/S1470-2045(22)00299-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 6 246 23.2022, 6, e246- |
allfields_unstemmed |
10.1016/S1470-2045(22)00299-6 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001787.pica (DE-627)ELV057857385 (ELSEVIER)S1470-2045(22)00299-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl André, Thierry verfasserin aut Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Diaz, Luis A oth Shiu, Kai-Keen oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:6 pages:246 https://doi.org/10.1016/S1470-2045(22)00299-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 6 246 23.2022, 6, e246- |
allfieldsGer |
10.1016/S1470-2045(22)00299-6 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001787.pica (DE-627)ELV057857385 (ELSEVIER)S1470-2045(22)00299-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl André, Thierry verfasserin aut Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Diaz, Luis A oth Shiu, Kai-Keen oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:6 pages:246 https://doi.org/10.1016/S1470-2045(22)00299-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 6 246 23.2022, 6, e246- |
allfieldsSound |
10.1016/S1470-2045(22)00299-6 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001787.pica (DE-627)ELV057857385 (ELSEVIER)S1470-2045(22)00299-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl André, Thierry verfasserin aut Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Diaz, Luis A oth Shiu, Kai-Keen oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:6 pages:246 https://doi.org/10.1016/S1470-2045(22)00299-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 6 246 23.2022, 6, e246- |
language |
English |
source |
Enthalten in My London volume:23 year:2022 number:6 pages:246 |
sourceStr |
Enthalten in My London volume:23 year:2022 number:6 pages:246 |
format_phy_str_mv |
Article |
bklname |
Biochemie: Allgemeines Biophysik |
institution |
findex.gbv.de |
dewey-raw |
570 |
isfreeaccess_bool |
false |
container_title |
My |
authorswithroles_txt_mv |
André, Thierry @@aut@@ Diaz, Luis A @@oth@@ Shiu, Kai-Keen @@oth@@ |
publishDateDaySort_date |
2022-01-01T00:00:00Z |
hierarchy_top_id |
ELV003173852 |
dewey-sort |
3570 |
id |
ELV057857385 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057857385</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625003307.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(22)00299-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001787.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057857385</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(22)00299-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">André, Thierry</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Diaz, Luis A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shiu, Kai-Keen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:246</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(22)00299-6</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2022</subfield><subfield code="e">6</subfield><subfield code="h">246</subfield><subfield code="y">23.2022, 6, e246-</subfield></datafield></record></collection>
|
author |
André, Thierry |
spellingShingle |
André, Thierry ddc 570 fid BIODIV bkl 35.70 bkl 42.12 Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply |
authorStr |
André, Thierry |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003173852 |
format |
electronic Article |
dewey-ones |
570 - Life sciences; biology |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply |
topic |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
topic_unstemmed |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
topic_browse |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
l a d la lad k k s kks |
hierarchy_parent_title |
My |
hierarchy_parent_id |
ELV003173852 |
dewey-tens |
570 - Life sciences; biology |
hierarchy_top_title |
My |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV003173852 |
title |
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply |
ctrlnum |
(DE-627)ELV057857385 (ELSEVIER)S1470-2045(22)00299-6 |
title_full |
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply |
author_sort |
André, Thierry |
journal |
My |
journalStr |
My |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
500 - Science |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
zzz |
container_start_page |
246 |
author_browse |
André, Thierry |
container_volume |
23 |
class |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
André, Thierry |
doi_str_mv |
10.1016/S1470-2045(22)00299-6 |
dewey-full |
570 |
title_sort |
crossing survival curves of keynote-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – authors' reply |
title_auth |
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
container_issue |
6 |
title_short |
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply |
url |
https://doi.org/10.1016/S1470-2045(22)00299-6 |
remote_bool |
true |
author2 |
Diaz, Luis A Shiu, Kai-Keen |
author2Str |
Diaz, Luis A Shiu, Kai-Keen |
ppnlink |
ELV003173852 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth |
doi_str |
10.1016/S1470-2045(22)00299-6 |
up_date |
2024-07-06T17:22:30.166Z |
_version_ |
1803851189634203648 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057857385</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625003307.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(22)00299-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001787.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057857385</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(22)00299-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">André, Thierry</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Diaz, Luis A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shiu, Kai-Keen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:246</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(22)00299-6</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2022</subfield><subfield code="e">6</subfield><subfield code="h">246</subfield><subfield code="y">23.2022, 6, e246-</subfield></datafield></record></collection>
|
score |
7.3996735 |